Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000441 · ClinicalTrials.gov registry record · Phase 4

Drug Therapy for Alcohol Detoxification

A Phase 4 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Completed
Registry status
Phase 4
Development phase

NCT00000441: Completed Phase 4 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

NCT00000441 is a Phase 4 study that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000441, a Phase 4 study, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

COMPLETED
Registry status
Phase 4
Development phase

Study Summary

This project will provide relevant clinical information for primary care practitioners treating alcohol withdrawal syndrome in outpatient settings. This double-blind, placebo- controlled clinical trial will compare the effectiveness of lorazepam (Ativan) and carbamazepine (Tegretol) in alcoholics who meet the criteria for a diagnosis of uncomplicated alcohol withdrawal syndrome. Participants are randomized to five days of treatment with a 1-week posttreatment followup.

Interventions

  • DRUG lorazepam (Ativan)
  • DRUG carbamazepine (Tegretol)

Trial Details

FieldValue
Est. Completion 2000-12
Phase Phase 4

What the finished NCT00000441 record still lists

NCT00000441 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 2 interventions - of which lorazepam (Ativan) is the first listed.

NCT00000441 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00000441 about?

NCT00000441 is a clinical study titled "Drug Therapy for Alcohol Detoxification". This project will provide relevant clinical information for primary care practitioners treating alcohol withdrawal syndrome in outpatient settings. This double-blind, placebo- controlled clinical trial will compare the effectiveness of lorazepam (Ativan) and carbamazepine (Tegretol) in alcoholics wh...

What is the current status of trial NCT00000441?

This trial is currently completed. It is a Phase 4 study. Estimated completion is 2000-12.

What interventions are being tested in trial NCT00000441?

The interventions under investigation include: lorazepam (Ativan) (DRUG), carbamazepine (Tegretol) (DRUG).

Who is sponsoring clinical trial NCT00000441?

This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.

Source: ClinicalTrials.gov NCT00000441, the US trial registry maintained by the National Library of Medicine. NCT00000441 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.